Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates
Are generalist investors good or bad for biotech? How did Elaine and Adam’s trip to…
Author: STAT
STAT+: FDA cites Granules, a large Indian generic drug manufacturer, for tossing truckloads of key documents
Amid ongoing concern over the quality of medicines made in India, a major supplier of…
STAT+: Senate panel votes to hold Steward Health Care CEO in contempt
A Senate committee on Thursday approved referring Steward Health Care chief executive Ralph de la…
STAT+: Lawmakers urge U.S. Patent Office and drug makers to correct patent mistakes
A group of lawmakers wants the U.S. Patent & Trademark Office and drug companies to…
Talkspace offers therapy via Amazon, and 23andMe board members resign
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology…
STAT+: Corbus shares will soar or dive soon. Here’s why
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
The Fed cut rates and biotech stocks… didn’t do much
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a rare-disease drug bill, compounded Wegovy, and more
Rise and shine, everyone, another busy day is on the way. However, this is shaping…
Long-overlooked scientist shares Lasker Award with other GLP-1 researchers
GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for…
STAT+: A new cell therapy company takes its vision from four founders, and its skin from George Church
Serial biotech founder George Church has a new startup, and this time, he has skin…
STAT+: Corbus sees Novo’s controversial obesity approach as a ticket to a blockbuster
NEW YORK — Nearly two decades ago, European regulators pulled an obesity drug called rimonabant off…
STAT+: FDA designates devices for heart surgery, smart knee implant as ‘breakthroughs’
Check out STAT’s exclusive breakthrough devices tracker. The latest medical devices to receive breakthrough status…
Opinion: A failing health care system caused my husband’s death
On Tuesday, the Centers for Disease Control and Prevention, the Centers for Medicare and Medicaid…
Q&A: Former NIH director Francis Collins on a Trump administration, science, and God
Francis Collins’ reputation precedes him: A scientist’s scientist, he obtained a Ph.D. in physical chemistry…
Opinion: Medicaid must prepare to cover twice-yearly HIV prevention injection
In June, a clinical trial showed that a twice-yearly injection was just as effective at…
STAT+: House panel passes pediatric rare disease bill, setting it up for government funding bill
A House committee on Wednesday passed a bill to renew a program aimed at aiding…
STAT+: House panel advances bill to extend Medicare’s telehealth flexibilities, setting up December talks
A House committee on Wednesday advanced legislation that would extend Medicare telehealth flexibilities and a…
STAT+: In race to make gene therapy for age-related blindness, 4D Molecular announces positive results
A long-running race to develop a gene therapy for the most common cause of age-related…
STAT+: Social media diss highlights high-stakes rivalry over colon cancer blood tests
Biotech companies routinely compete to develop and commercialize products. But these rivalries are seldom as…
STAT+: Hospital giant Ascension recorded about $1.3 billion in losses from its cyberattack
The cyberattack that forced Ascension to shut off access to its electronic health records cost…
Vance on ACA, diagnosing myopia, and fallout from a retracted study
In a story today from STAT’s Anil Oza, I learned that researcher and physician Alex…
Bernie Sanders keeps the heat on Novo’s high prices
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about pharma patent maneuvers, the U.S. warning J&J, and more
Hello, everyone, and how are you today? We are muddling along, but the middle of…
STAT+: Roivant strikes another deal, selling dermatology spinoff to Organon in deal worth $1.2 billion
Roivant Sciences continues its dealmaking hot streak, announcing Wednesday that it would sell one of…
Year-long fallout over retracted trans youth paper highlights new research era
Last year, a Springer Nature journal published a study surveying 1,700 parents of adolescents and…
Opinion: The U.S. should follow California’s lead on banning toxic chemicals in IV bags and tubes
In 2017, at the age of 42, Susan Whitehead was diagnosed with an early form…
Opinion: Tested in Africa, used in America
At the recent annual International AIDS Conference, a startling presentation about the newest wonder drug…
STAT+: Drugmakers rely on ‘use codes’ to vastly expand the nature of their patent claims, STAT analysis shows
Amid debate over potential abuse of the U.S. patent system by the pharmaceutical industry, moves…
FDA awards Novartis expanded approval for breast cancer therapy
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated…
Senate IVF bill fails again as Democrats pressure GOP on reproductive health
WASHINGTON — The Senate failed again Tuesday to advance legislation that would protect access to…
Vance’s confusing health insurance remarks give Democrats a new attack line
GOP Vice Presidential-hopeful JD Vance made some confusing comments over the weekend about deregulating health…
STAT+: U.S. agency threatens J&J with sanctions if it switches payments to 340B hospitals
A U.S. government agency has threatened Johnson & Johnson with sanctions if the company proceeds…
STAT+: From Epic to FDA, all the leaders presenting at HHS’ invite-only AI in health care event
Federal health officials wrestling with when and how to use artificial intelligence will on Wednesday…
STAT+: Democrats keep IVF in the spotlight with another Senate vote
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
FDA formalizes protocol for international cancer trials
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about an Express Scripts lawsuit against FTC, AMR deaths, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Express Scripts sues FTC over a ‘biased’ report about pharmacy benefit managers
Express Scripts, one of the largest pharmacy benefit managers in the U.S., filed a lawsuit…
STAT+: 11 people shaping psychedelics drug development
The field of psychedelics, once relegated to the fringes of science and medicine, is in…
STAT+: What pharma companies and insurers think about Medicare’s plan to cover digital treatments
In July, Medicare proposed to start paying for some mental health apps, in a move…
A documentary film asks: Can health systems improve patient safety by embracing new tech?
Reetam Ganguli once pitched his technology, to rescue women from pregnancy complications, in an airplane…
Opinion: WHO pandemic threat director: Here’s what needs to happen to combat mpox
There is a pervasive myth that the Democratic Republic of the Congo and other countries…
A history of mpox so far
Read Original Article: A history of mpox so far »
STAT+: Most cardiovascular devices with serious safety recalls aren’t tested in patients
When someone’s heart doesn’t beat quite right, an implantable defibrillator can save their life. The…
Could new childhood obesity guidelines fuel eating disorders?
Good morning! For a limited time, you can get your first three months of a…
The news from ESMO: An immunotherapy milestone, studying young-onset cancers, and more
This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the…
STAT+: What Medicare Advantage enrollment could look like for next year
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
STAT+: After 10 years of game-changing immunotherapies, a cancer conference celebrates — and sees more work to do
BARCELONA, Spain — Ten years ago, a new type of cancer treatment reached the market….
STAT+: Top staffer on drug pricing to depart Senate Finance Committee
WASHINGTON – Shawn Bishop, the Democratic staffer who drafted much of the drug pricing portion…
STAT+: Pharmalittle: We’re reading about an AstraZeneca bladder cancer drug, Genentech anxiety, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
The essential biotech updates of the day
Morning! Today, we talk about bioethics, catch up on some reports from ESMO, and wonder aloud…